Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Bo Lagerqvist
Prof. Gilles Montalescot,
By Bo Lagerqvist, (Uppsala, Sweden)View Discussant report
Open the PresentationWatch the Webcast
List of Authors: Bo Lagerqvist, MD, PhD,1,2), Ole Fröbert, MD, PhD3), Göran K. Olivecrona, MD, PhD 4), Thórarinn Gudnason, MD, PhD 5), Michael Maeng, MD, PhD 6), Ollie Östlund, MSc 2) Stefan K. James, MD. PhD,1,2)1) Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden2) Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.3) Department of Cardiology, Örebro University Hospital, Örebro, Sweden.4) Department of Cardiology, Lund University Hospital Lund, Sweden.5) Department of Cardiology, Landspitali Univesity Hospital, Reykjavik, Iceland.6) Department of Cardiology, Skejby Hospital, Aarhus University Hospital, Aarhus, Denmark.
BackgroundThe Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial) randomized 7244 patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) to thrombus aspiration before PCI or PCI alone. The 30-day primary endpoint of all-cause mortality did not differ between the randomized groups. Here we report the preliminary 1-year outcome results.MethodsTASTE introduced the Registry-based Randomized Clinical Trial (RRCT) concept using national registries as on-line platforms for randomization, case record forms and follow-up in Sweden, Denmark and Iceland. ResultsNo patients were lost to follow-up for the primary endpoint. All-cause mortality was 5.3% (191 of 3621) in the thrombus aspiration group compared to 5.6% (202 of 3623) in the PCI alone group (hazard ratio (HR) 0.94; 95% confidence interval (CI), 0.78–1.15, P=0.57). Hospitalization for myocardial infarction during one year occurred in 2.7% (96) vs. 2.7% (99) (HR 0.97; 95% CI, 0.73–1.28, P=0.81) and stent thrombosis in 0.7% (27) vs. 0.9 % (32) (HR 0.84; 95% CI, 0.50 - 1.40, P=0.51). The composite of death, myocardial infarction and stent thrombosis occurred in 8.0% (289) vs. 8.5% (307) (HR 0.94; 95% CI 0.80-1.11, P=0.48). ConclusionsThrombus aspiration as a routine adjunct to primary PCI does not reduce mortality or ischemic events on long term.
By Gilles Montalescot, FESC (Paris, France)See Presenter abstract
Open the presentationWatch the Webcast
Clinical Trial Update Hot Line: Infarction, interventions and outcome